Advances in the molecular mechanisms underlying progestin resistance in endometrial cancer

IF 6.3 3区综合性期刊 Q1 Multidisciplinary

Fundamental Research Pub Date : 2025-09-01 DOI:10.1016/j.fmre.2023.07.008

Jie Liu , Jingyi Zhou , Yiqin Wang , Fengxia Xue , Xiaojun Chen , Gang Chen , Jianliu Wang

{"title":"Advances in the molecular mechanisms underlying progestin resistance in endometrial cancer","authors":"Jie Liu , Jingyi Zhou , Yiqin Wang , Fengxia Xue , Xiaojun Chen , Gang Chen , Jianliu Wang","doi":"10.1016/j.fmre.2023.07.008","DOIUrl":null,"url":null,"abstract":"<div><div>The incidence of endometrial cancer (EC) has been on the rise, with a notable increase observed in younger female population. Approximately 80% of EC patients are associated with endometrial hyperplasia, a condition characterized by excessive stimulation from unopposed estrogen. Progestin, as the antagonist of estrogen, is recommended for patients with fertility conservation requirements. However, some patients may exhibit insensitivity to progestin treatment, and those with comorbidities such as obesity and diabetes may experience suboptimal therapeutic effects. To improve the efficacy of progestin treatment and address the fertility needs of patients, it is imperative to elucidate the underlying mechanisms of progestin insensitivity in EC. In this review, we explore the role of progestin in EC and its clinical effectiveness. We discuss the factors contributing to progestin insensitivity, highlight recent advancements in research aimed at enhancing treatment sensitivity, and propose potential avenues for future investigation.</div></div>","PeriodicalId":34602,"journal":{"name":"Fundamental Research","volume":"5 5","pages":"Pages 2330-2342"},"PeriodicalIF":6.3000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fundamental Research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667325823002443","RegionNum":3,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Multidisciplinary","Score":null,"Total":0}

引用次数: 0

Abstract

The incidence of endometrial cancer (EC) has been on the rise, with a notable increase observed in younger female population. Approximately 80% of EC patients are associated with endometrial hyperplasia, a condition characterized by excessive stimulation from unopposed estrogen. Progestin, as the antagonist of estrogen, is recommended for patients with fertility conservation requirements. However, some patients may exhibit insensitivity to progestin treatment, and those with comorbidities such as obesity and diabetes may experience suboptimal therapeutic effects. To improve the efficacy of progestin treatment and address the fertility needs of patients, it is imperative to elucidate the underlying mechanisms of progestin insensitivity in EC. In this review, we explore the role of progestin in EC and its clinical effectiveness. We discuss the factors contributing to progestin insensitivity, highlight recent advancements in research aimed at enhancing treatment sensitivity, and propose potential avenues for future investigation.

查看原文本刊更多论文

子宫内膜癌中黄体酮耐药的分子机制研究进展

子宫内膜癌（EC）的发病率一直呈上升趋势，其中年轻女性的发病率显著上升。大约80%的EC患者伴有子宫内膜增生，这是一种以未对抗雌激素过度刺激为特征的疾病。黄体酮作为雌激素的拮抗剂，推荐用于有生育能力保持要求的患者。然而，一些患者可能对黄体酮治疗不敏感，而那些有合并症（如肥胖和糖尿病）的患者可能会经历次优的治疗效果。为了提高黄体酮的治疗效果，满足患者的生育需求，有必要阐明黄体酮不敏感的潜在机制。本文就黄体酮在EC中的作用及其临床疗效进行综述。我们讨论了导致黄体酮不敏感的因素，强调了旨在提高治疗敏感性的研究的最新进展，并提出了未来研究的潜在途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊